Standardizing the use of the Continuous Performance Test in schizophrenia research: A validation study

Schizophrenia Research

Volumn 142, Issue 1-3, 2012, Pages 153-158

  Kahn, Phoebe V ^a   Walker, Trina M ^a   Williams, Teresa S ^b   Cornblatt, Barbara A ^c   Mohs, Richard C ^b   Keefe, Richard S E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Attention; Continuous Performance Test; CPT; Neuropsychological assessment; Schizophrenia

Indexed keywords

ADULT; ARTICLE; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA; CLINICAL ARTICLE; CONTINUOUS PERFORMANCE TEST; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FOUR DIGIT IDENTICAL PAIRS CONTINUOUS PERFORMANCE TEST; HUMAN; INTERMETHOD COMPARISON; MALE; MENTAL PERFORMANCE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; PSYCHOMETRY; QUESTIONNAIRE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SHAPES IDENTICAL PAIRS CONTINUOUS PERFORMANCE TEST; STANDARDIZATION; THREE DIGIT IDENTICAL PAIRS CONTINUOUS PERFORMANCE TEST; TWO DIGIT IDENTICAL PAIRS CONTINUOUS PERFORMANCE TEST; VALIDATION PROCESS;

ADULT; ATTENTION; BRIEF PSYCHIATRIC RATING SCALE; COGNITION DISORDERS; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84869868719     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.09.009     Document Type: Article

References (26)

1. Arsanow R.F., MacCrimmon D.J. Residual performance deficit in clinically remitted schizophrenics: a marker of schizophrenia?. J. Abnorm. Psychol. 1978, 86:267-275.
2. Birchwood M., Smith J., Cochrane R., Wetton S., Copestake S. The social functioning scale: the development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients. Br. J. Psychiatry 1990, 157:853-859.
3. Blanchard J.J., Neale J.M. The neuropsychological signature of schizophrenia: generalized or differential deficit?. Am. J. Psychiatry 1994, 151(1):40-48.
4. Cornblatt B.A., Keilp J.G. Impaired attention, genetics, and the psychopathology of schizophrenia. Schizophr. Bull. 1994, 20(1):31-46.
5. Cornblatt B.A., Malhotra A.K. Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am. J. Med. Genet. 2001, 105:11-15.
6. Cornblatt B.A., Risch N.J., Faris G., Friedman D.Erlenmeyer, Kimling L. The Continuous Performance Test, Identical Pairs Version (CPT-IP): I. New Findings about sustained attention in normal families. Psychiatry Res. 1988, 26:223-238.
7. Cornblatt B.A., Lenzenweger M.F., Erlenmeyer-Kimling L. The continuous performance test, identical pairs version: II. Contrasting attention profiles in schizophrenic and depressed patients. Psychiatry Res. 1989, 29(1):65-85.
8. Green M.F. Mediators between neurocognitive deficits and community outcome in schizophrenia. J. Adv. Schizophr. Brain Res. 2002, 4:3-7.
9. Gur R.C., Ragland J.D., Gur R.E. Cognitive changes in schizophrenia - a critical look. Int. Rev. Psychiatry 1997, 9:449-457.
10. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, Revised, US Department of Health, Education, and Welfare, Bethesda, Maryland.
11. Harvey P.D., Keefe R.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 2001, 158(2):176-184.
12. Harvey P.D., Keefe R.S.E., Moskowitz J., Putnam K.M., Mohs R.C., Davis K.L. Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals. Psychiatry Res. 1990, 33:179-188.
13. Harvey P.D., Raykov T., Twamley E.W., Vella L., Heaton R.K., Patterson T.L. Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. Am. J. Psychiatry 2011, 168:1195-1201.
14. Hedges L.V., Olkin I. Statistical Methods for Meta-analysis 1985, Academic Press, Inc., Orlando.
15. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
16. Kay S.R., Fiszbein A., Opher L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
17. Keefe R.S.E., Seidman L.J., Christensen B.K., Hamer R.M., Sharma T., Sitskoorn M., Lewine R.R.J., Yurgelun-Todd D., Gur R.C., Tohen M., Tollefson G.M., Sanger T.M., Lieberman J.A. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized double-blind trial of olanzapine versus low-dose haloperidol. Am. J. Psychiatry 2004, 161:985-995.
18. Keefe R.S.E., Goldberg T.E., Harvey P.D., Gold J.M., Poe M., Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004, 68:283-297.
19. Keefe R.S.E., Bilder R.M., Harvey P.D., Davis S.M., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Miller D.D., Canive J.M., Adler L.W., Manschreck T.C., Swartz M., Rosenheck R., Perkins D.O., Walker T.M., Stroup T.S., McEvoy J.P., Lieberman J.A. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006, 31:2033-2046.
20. Keefe R.S.E., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 2007, 64:633-647.
21. Kurtz M.M., Ragland J.D., Bilker W., Gur R.C., Gur R.E. Comparison of the continuous performance test with and without working memory demands in healthy controls and patients with schizophrenia. Schizophr. Res. 2001, 48:307-316.
22. Nelson E.B., Sax K.W., Strakowski S.M. Attentional performance in patients with psychotic and nonpsychotic major depression and schizophrenia. Am. J. Psychiatry 1998, 155:137-139.
23. Orzack M.H., Kornetsky C. Attention dysfunction in chronic schizophrenia. Arch. Gen. Psychiatry 1966, 14:323-326.
24. Rosvold H.E., Mirsky A., Sarason I., Bransome E.D., Beck L.H. A continuous performance test of brain damage. J. Consult. Clin. Psychol. 1956, 20(5):343-350.
25. Serper M.R., Bergman R.L., Harvey P.D. Medication may be required for the development of automatic information processing in schizophrenia. Psychiatry Res. 1990, 32:281-288.
26. Ware J.E., Snow K.K., Kosinski M., Gandek B. SF-36 Health Survey Manual and Interpretation Guide 1993, The Health Institute, New England Medical Center, Boston, MA.